Trxade Health, Inc. (NASDAQ: MEDS), a leading health services IT company, and its wholly owned subsidiary Scienture, LLC revealed that Trxade has
TRxADE Health changes its name to Scienture Holdings
Categories
Health Care
IPO News: Everything you need to know about BioAge Labs’ IPO
BioAge Labs, Inc. is the latest among the healthcare companies pursuing stock-market listing this year. In a registration statement filed with the
Guardian Pharmacy seeks to raise up to $108 mil in US IPO
Joining the wave of healthcare IPOs this year, amid Fed rate cut expectations, Guardian Pharmacy Services, Inc. is preparing to go public.
Everything you need to know about Zenas BioPharma’s IPO
Zenas BioPharma, Inc. is among the latest healthcare companies to jump on the IPO bandwagon, filing its prospectus even as the market
Ocean Biomedical (NASDAQ: OCEA) Research Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a preclinical biotech company focused on moving new therapeutic candidates efficiently from the laboratory to the
Medtronic bets on innovation and new technology to drive long-term growth
Over the years, Medtronic plc (NYSE: MDT) has constantly strengthened its position in the medical device industry by innovating the product portfolio
Medtronic (MDT) reports higher revenue and profit for Q1 2025
Medical device maker Medtronic plc (NYSE: MDT) reported an increase in revenues and adjusted profit for the first quarter of 2025. First-quarter
Trxade Health (MEDS) Q2 2024 Research Summary
Trxade Health, Inc. (NASDAQ: MEDS) is a drug procurement and delivery platform with a mission to revolutionize the healthcare industry by offering
Earnings Summary: Highlights of Cardinal Health’s (CAH) Q4 2024 results
Cardinal Health (NYSE: CAH), a leading pharmaceuticals distributor, on Wednesday reported an increase in revenues and adjusted profit for the fourth quarter
MEDS Earnings: A snapshot of Trxade’s Q2 2024 results
Health services IT company Trxade Health, Inc. (NASDAQ: MEDS) announced financial results for the second quarter of 2024, reporting a narrower net
Earnings Summary: Gilead Sciences reports higher Q2 revenue and profit
Gilead Sciences, Inc. (NASDAQ: GILD), a leading research-based biopharmaceutical company, has reported an increase in revenues and adjusted earnings for the second
LLY Earnings: Highlights of Eli Lilly’s Q2 2024 financial report
Eli Lilly and Company (NYSE: LLY) on Thursday reported a double-digit increase in revenues and profit for the second quarter of 2024.
Earnings Summary: A snapshot of Bio-Techne’s (TECH) Q4 2024 results
Biotechnology company Bio-Techne Corporation (NASDAQ: TECH) on Wednesday announced financial results for the fourth quarter of 2024, reporting a decline in profit.
CVS Earnings: CVS Health Q2 adj. profit drops but beats estimates
Healthcare conglomerate CVS Health Corporation (NYSE: CVS) on Wednesday announced second-quarter 2024 results, reporting a decrease in adjusted earnings despite higher revenues.
CVS Health to report Q2 2024 results on Wednesday. Here’s what to expect
Healthcare conglomerate CVS Health Corporation (NYSE: CVS) had a modest start to fiscal 2024, with sales and profit coming under pressure from
Earnings Summary: Moderna reports Q2 2024 financial results
Biotechnology company Moderna, Inc. (NASDAQ: MRNA) Thursday reported a sharp decline in revenues for the second quarter of 2024. Second-quarter revenues decreased
Biogen (BIIB) Q2 2024 Earnings: Key financials and quarterly highlights
Biogen Inc. (NASDAQ: BIIB) reported its second quarter 2024 earnings results today. Total revenue of $2.5 billion was flat at actual currency
Earnings Summary: Highlights of Humana’s Q2 2024 report
Humana Inc. (NYSE: HUM), a leading health and well-being company, reported a decrease in adjusted earnings for the second quarter of 2024
Merck (MRK) swings to profit in Q2 on higher revenues; earnings beat
Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported net profit for the second quarter of 2024, on an adjusted basis, compared
Pfizer (PFE) Q2 2024 Earnings: Key financials and quarterly highlights
Pfizer Inc. (NYSE: PFE) reported its second quarter 2024 earnings results today. Revenues increased 2% year-over-year to $13.3 billion. Revenues grew 3%
Earnings Summary: A snapshot of DexCom’s Q2 2024 financial results
Healthcare company DexCom, Inc. (NASDAQ: DXCM) has reported an increase in revenue and adjusted earnings for the second quarter of 2024. The